Partial Thromboplastin Time
"Partial Thromboplastin Time" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.
| Descriptor ID |
D010314
|
| MeSH Number(s) |
E01.370.225.625.115.600 E05.200.625.115.600 G09.188.660
|
| Concept/Terms |
Kaolin-Cephalin Coagulation Time- Kaolin-Cephalin Coagulation Time
- Coagulation Time, Kaolin-Cephalin
- Kaolin Cephalin Coagulation Time
- Coagulation Time, Cephalin-Kaolin
- Coagulation Time, Cephalin Kaolin
- Cephalin-Kaolin Coagulation Time
- Cephalin Kaolin Coagulation Time
|
Below are MeSH descriptors whose meaning is more general than "Partial Thromboplastin Time".
Below are MeSH descriptors whose meaning is more specific than "Partial Thromboplastin Time".
This graph shows the total number of publications written about "Partial Thromboplastin Time" by people in this website by year, and whether "Partial Thromboplastin Time" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 2004 | 0 | 3 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Partial Thromboplastin Time" by people in Profiles.
-
Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 08 12; 385(7):609-617.
-
Patientem Fortuna Adiuvat: The Delayed Treatment of Surgical Acute Subdural Hematomas-A Case Series. World Neurosurg. 2018 Dec; 120:e414-e420.
-
Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy. Curr Drug Targets. 2016; 17(8):954-70.
-
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015 Jan 15; 372(3):232-40.
-
Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev. 2012 Jan; 26(1):1-13.
-
In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. Thromb Haemost. 2009 May; 101(5):827-33.
-
Use of recombinant factor VIIa (NovoSeven) in pediatric cardiac surgery. J Extra Corpor Technol. 2008 Dec; 40(4):241-8.
-
The effects of argatroban on thrombin generation and hemostatic activation in vitro. Anesth Analg. 2004 Nov; 99(5):1283-1289.
-
Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care. 2004 Apr; 8(2):R82-90.
-
Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. Thromb Res. 2004; 113(5):333-9.